Relapsed/Refractory B-cell Malignancies Clinical Trial
Official title:
An Open-label Study to Assess the Long-term Safety and Efficacy of ONO/GS-4059 in Subjects With Relapsed/Refractory B-cell Malignancies
The primary objective of this study is to determine the long-term safety and tolerability of tirabrutinib in adults with relapsed/refractory B-cell malignancy who have tolerated and achieved stable disease or improved with tirabrutinib treatment while enrolled in a prior (parent study) tirabrutinib study (NCT01659255). The dosing regimen will be based on the prior dosing regimen from the parent study.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05780034 -
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT04943016 -
CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04689308 -
This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04861779 -
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies
|
Phase 1 |